Ironwood Pharmaceuticals Dividends
| IRWD Stock | USD 3.62 0.12 3.21% |
The current year's Dividends Paid is expected to grow to about 134.2 M. The current year's Dividend Paid And Capex Coverage Ratio is expected to grow to 3,923. Ironwood Pharmaceuticals' past performance could be the main factor of why investors trade Ironwood Pharmaceuticals stock today. Investors should clearly understand every aspect of the Ironwood Pharmaceuticals dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Ironwood Pharmaceuticals' dividend schedule and payout information. Ironwood Pharmaceuticals dividends can also provide a clue to the current valuation of Ironwood Pharmaceuticals.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 127.8 M | 134.2 M | |
| Dividend Paid And Capex Coverage Ratio | 3.7 K | 3.9 K |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Ironwood Pharmaceuticals must own a stock before its ex-dividend date to receive its next dividend.
Ironwood Pharmaceuticals Dividends Paid Over Time
Today, most investors in Ironwood Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ironwood Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's dividends paid growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Ironwood Pharmaceuticals dividends paid as a starting point in their analysis.
The total amount of dividends that a company has paid out to its shareholders over a specific period. Dividends Paid |
| Timeline |
Will Biotechnology sector continue expanding? Could Ironwood diversify its offerings? Factors like these will boost the valuation of Ironwood Pharmaceuticals. Market participants price Ironwood higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ironwood Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 10.468 | Earnings Share 0.15 | Revenue Per Share | Quarterly Revenue Growth (0.47) | Return On Assets |
Investors evaluate Ironwood Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Ironwood Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Ironwood Pharmaceuticals' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Ironwood Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.